[A new therapeutic approach to open pulmonary tuberculosis with a combination of isoniazid, prothionamid and dapson (author's transl)].
D000293:Adolescent; D000328:Adult; D003622:Dapsone / Q000627:therapeutic use*; D004338:Drug Combinations; D004341:Drug Evaluation; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use*; D007539:Isonicotinic Acids / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification; D011515:Prothionamide / Q000627:therapeutic use*; D013183:Sputum / Q000382:microbiology; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D004338:Drug Combinations; D007539:Isonicotinic Acids; D011515:Prothionamide; D003622:Dapsone; D007538:Isoniazid
Klinische Erfahrungen mit einem neuen Behandlungssystem (Isoniazid + Prothionamid + Dapson) bei mikroskopisch positiver Lungentuberkulose.